RT Journal Article
SR Electronic
T1 Biopsy-free prediction of prostate cancer aggressiveness using deep learning and radiology imaging
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.16.19015057
DO 10.1101/2019.12.16.19015057
A1 Pegah Khosravi
A1 Maria Lysandrou
A1 Mahmoud Eljalby
A1 Matthew Brendel
A1 Qianzi Li
A1 Ehsan Kazemi
A1 Josue Barnes
A1 Pantelis Zisimopoulos
A1 Alexandros Sigaras
A1 Camir Ricketts
A1 Dimitri Meleshko
A1 Andy Yat
A1 Timothy D. McClure
A1 Brian D. Robinson
A1 Andrea Sboner
A1 Olivier Elemento
A1 Bilal Chughtai
A1 Iman Hajirasouliha
YR 2019
UL http://medrxiv.org/content/early/2019/12/19/2019.12.16.19015057.abstract
AB Magnetic Resonance Imaging (MRI) is routinely used to visualize the prostate gland and manage prostate cancer. The Prostate Imaging Reporting And Data System (PI-RADS) is used to evaluate the clinical risk associated with a potential tumor. However the PI-RADS score is subjective and its assessment varies between physicians. As a result, a definite diagnosis of prostate cancer requires a biopsy to obtain tissue for pathologic analysis. A prostate biopsy is an invasive procedure and is associated with complications, including hematospermia, hematuria, and rectal bleeding.We hypothesized that an Artificial Intelligence (AI) can be trained on prostate cases where both imaging and biopsy are available to distinguish aggressive prostate cancer from non-aggressive lesions using MRI imaging only, that is, without the need for a biopsy.Our computational method, named AI-biopsy, can distinguish aggressive prostate cancer from non-aggressive disease with an AUC of 0.855 and a 79.02% accuracy. We used Class Activation Maps (CAM) to highlight which regions of MRI images are being used by our algorithm for classification, and found that AI-biopsy generally focuses on the same regions that trained uro-radiolosts focus on, with a few exceptions. In conclusion, AI-biopsy provides a data-driven and reproducible way to assess cancer aggressiveness from MRI images and a personalized strategy to reduce the number of unnecessary biopsies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported using start-up funds (Weill Cornell Medicine) to Iman HajirasoulihaAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe links to the publicly available data sets from TCIA are available below: The public data obtained from TCIA: https://www.cancerimagingarchive.net/ PROSTATEx https://wiki.cancerimagingarchive.net/display/Public/SPIE-AAPM-NCI+PROSTATEx+Challenges PROSTATE DIAGNOSIS https://wiki.cancerimagingarchive.net/display/Public/PROSTATE-DIAGNOSIS PROSTATE MRI https://wiki.cancerimagingarchive.net/display/Public/PROSTATE-MRI https://www.cancerimagingarchive.net/ https://wiki.cancerimagingarchive.net/display/Public/SPIE-AAPM-NCI+PROSTATEx+Challenges https://wiki.cancerimagingarchive.net/display/Public/PROSTATE-DIAGNOSIS https://wiki.cancerimagingarchive.net/display/Public/PROSTATE-MRI